AbbVie Inc. (NYSE: ABBV) ended Thursday’s session modestly lower, then ticked higher in after-hours trading as investors digested a fresh mix of U.S. drug-pricing policy headlines and broader pharma news that could shape sentiment into Friday’s open.
AbbVie stock price after the bell (Dec. 18, 2025)
AbbVie shares closed at $222.82, down 0.66% on the day. The stock traded between $222.79 and $226.26, with about 4.76 million shares changing hands.
In the after-hours session, ABBV rose to $223.51, up 0.31%, as of the evening update shown on Investing.com.
For context, the S&P 500 finished up 0.79% on Thursday, meaning AbbVie lagged the broader tape during regular trading hours.
Why AbbVie is in focus tonight: the headline risk is Washington, not earnings
There wasn’t a major new AbbVie-specific earnings release after today’s close. Instead, policy and pricing headlines are the dominant “overnight” variable for large-cap pharma stocks—AbbVie included—heading into Friday.
1) A White House drug-pricing announcement is expected Friday — and AbbVie is on the list being discussed
Reuters reported that AbbVie and several other drugmakers are expected to announce agreements with the U.S. government on Friday aimed at lowering certain prescription drug prices and meeting other policy demands tied to President Donald Trump’s “most-favored-nation” (MFN) pricing initiative. Reuters
Key details from the Reuters reporting that matter for ABBV traders overnight:
- The announcement is expected to involve about five companies (per sources).
- Reuters also reported the administration is expected to unveil details of a test project tying Medicare payments to the lowest prices drugmakers charge in a select group of other nations.
- Bloomberg was cited by Reuters as reporting the White House could announce deals with Novartis and Roche, with broader implications for pharma pricing optics and (potentially) trade tensions.
What this means before Friday’s open: if premarket headlines confirm AbbVie’s participation, investors will quickly try to answer two questions:
- Scope: Which products or programs are included (Medicaid only vs. broader spillover concerns)?
- Materiality: Is it mostly a “headline clearing event” (limited direct financial impact), or does it create a new pricing precedent investors must re-rate across the sector?
Reuters noted that, if the deals resemble prior formats, some analysts see announcements as a kind of “clearing event” for stock prices—reducing uncertainty even if the policy direction stays the same. Reuters
2) Medicare negotiated prices and out-of-pocket shifts are becoming more concrete — and AbbVie’s Imbruvica is specifically mentioned
A separate Reuters report (citing an AARP analysis) said Americans enrolled in Medicare could pay about 50% less out of pocket in 2026 for some drugs among the first 10 products with negotiated prices under the Inflation Reduction Act framework—because coinsurance calculations change as negotiated prices take effect.
AbbVie is directly relevant here: Reuters notes that patients taking AbbVie’s Imbruvica, along with Amgen’s Enbrel and J&J’s Stelara, may still face higher monthly out-of-pocket costs (roughly $600 to $2,800 per month), even with the broader policy shift.
Also important for longer-range forecasting: the same Reuters report highlights a new Medicare out-of-pocket cap of $2,100 per year in 2026.
Takeaway for ABBV: investors will likely treat the MFN deal chatter and IRA implementation details as part of the same overarching theme—how durable U.S. pricing power will be for large-cap pharma in 2026 and beyond.
3) Competitive pressure in immunology: Takeda’s late-stage psoriasis pill puts a spotlight on AbbVie’s blockbuster Skyrizi franchise
Reuters also reported Thursday that Takeda said its AI-developed experimental pill for plaque psoriasis, zasocitinib, succeeded in two late-stage studies and is planned for regulatory submissions in 2026.
If eventually approved, Reuters notes it would enter a crowded market that includes injectables such as AbbVie’s Skyrizi (as well as J&J’s Tremfya and Novartis’ Cosentyx) plus oral competitors like Sotyktu and Otezla.
This isn’t an “ABBV-specific” catalyst today, but it matters because AbbVie’s post-Humira growth narrative leans heavily on immunology expansion—and Wall Street tends to react when credible new entrants show strong efficacy in large categories.
Today’s analyst tone on AbbVie: price targets still imply upside, but valuation is a debate
Even with Thursday’s dip, many Wall Street forecasts still point to mid-single to low-double-digit upside from current levels—though the “why” differs by shop.
Where consensus targets sit right now
- MarketBeat’s compiled consensus (as cited in its Dec. 18 coverage) lists a consensus target price around $245.84 and an overall “Moderate Buy” stance based on the distribution of Buy/Hold ratings it tracks. MarketBeat+1
- Investing.com’s page shows an analyst sentiment of “Buy” and a displayed price target of $244.68 (with upside calculated off the then-current price). Investing.com+1
The bullish-vs.-cautious split in today’s commentary
A widely circulated Motley Fool analysis published late Thursday frames AbbVie as an “investment of contradictions”: strong business and shareholder returns, but the stock’s valuation and recent earnings noise keep some investors cautious. The Motley Fool
Specifically, the piece points to:
- A weak-looking third-quarter earnings picture on a GAAP basis (with a charge related to acquisitions playing a big role), even as revenue growth held up.
- AbbVie’s raised full-year guidance and its dividend increase as offsets to the “bad headline” earnings optics. The Motley Fool
Separately, Reuters’ MFN story also included a key sentiment marker: the idea that these announcements can reduce policy overhang and uncertainty, which can matter just as much as the fine print for near-term trading.
What matters most before the stock market opens tomorrow (Friday, Dec. 19)
Here’s the practical checklist for anyone watching ABBV stock into Friday’s bell.
1) Premarket headlines on MFN pricing deals (highest impact)
Because Reuters reported an announcement is expected Friday, any confirmed participant list (and any early detail on scope/products) could move ABBV in premarket trading.
What to watch for immediately:
- Is AbbVie explicitly named in the announcement?
- Are the terms framed as Medicaid-only, or do they hint at Medicare expansion?
- Does the administration include detail on the Medicare “test project” tying payments to foreign-market price benchmarks?
2) Watch ABBV’s after-hours direction vs. regular-session weakness
ABBV slipped in the cash session but moved slightly higher after hours (per Investing.com’s after-hours print). If the stock opens above Thursday’s close, traders will interpret it as a tentative “policy-headline shrug.” If it opens below the day’s low, the market may be pricing in higher policy risk. Investing.com+1
3) Options expiration can amplify short-term moves
Friday is a standard monthly options expiration date on the 2025 options calendar, which can sometimes intensify end-of-week flows in heavily owned large-cap stocks.
This doesn’t change AbbVie’s fundamentals—but it can change how sharp intraday moves feel if big positioning rolls or unwinds.
4) Key technical reference levels traders will likely use
Based on Thursday’s range:
- Near-term support area: around $222.79 (Thursday’s low)
- Near-term resistance area: around $226.26 (Thursday’s high)
If policy news is benign, a move back toward the mid-$220s highs is plausible. If policy news surprises negatively, traders will watch whether the stock breaks and holds below Thursday’s lows.
5) Keep an eye on immunology “category read-through”
Takeda’s psoriasis pill news is not an overnight AbbVie event, but it reinforces how closely the market watches threats around immunology blockbusters like Skyrizi. Any additional analyst notes Friday that compare efficacy/safety/commercial potential could create incremental pressure or support across the space.
Bottom line for AbbVie stock heading into Friday
AbbVie’s Thursday close was relatively calm by single-stock standards, but the overnight setup is unusually headline-driven: Reuters’ reporting that drug-pricing agreements may be announced Friday places policy risk—and potential “uncertainty relief”—front and center for ABBV into the open. Reuters
At the same time, today’s analysis and consensus targets suggest the Street still sees meaningful upside from current levels, with the debate shifting to valuation and how pricing policy evolves in 2026.
